-
目前恶性肿瘤的发病率和病死率逐年升高,严重威胁人类的生命健康,其治疗方式多样化,包括手术治疗、放疗和化疗等,然而恶性肿瘤患者的5年生存率仍较低。近年来,程序性死亡受体1(programmed cell death protein 1,PD-1)/程序性死亡配体1(programmed death ligand 1,PD-L1)免疫治疗的兴起,改善了多种恶性肿瘤患者的预后,但部分患者未见临床获益,且缺乏相应预测其治疗疗效的生物标志物,导致部分患者疾病进展。18F-FDG PET/CT作为一种非侵入性的分子影像学技术,能准确评估肿瘤生物靶点的动态变化以及整体反映恶性肿瘤的糖代谢水平。相关研究结果表明,PD-L1阳性表达的肿瘤可通过糖代谢竞争进一步促进肿瘤免疫逃逸[1]。故我们综述18F-FDG PET/CT在肿瘤PD-1/PD-L1免疫治疗中的研究进展。
18F-FDG PET/CT在肿瘤PD-1/PD-L1免疫治疗中的研究进展
Advances of 18F-FDG PET/CT in PD-1/PD-L1 targeted immumotherapy of tumors
-
摘要: 程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)信号通路产生负性调控信号介导肿瘤免疫逃逸,导致肿瘤免疫耐受,促进其进展。而PD-1/PD-L1免疫治疗可恢复肿瘤微环境的免疫反应,介导T细胞增殖、活化,杀伤相关肿瘤细胞,为恶性肿瘤的治疗提供新方法。但不同患者对免疫治疗疗效存在差异性,至今仍缺乏有效的生物标志物鉴别应答者与非应答者。18F-FDG PET/CT能够无创、实时、整体地反映肿瘤的糖代谢水平,PD-L1阳性表达也影响肿瘤微环境的糖代谢水平。因此,18F-FDG PET/CT显像有望指导肿瘤PD-1/PD-L1免疫治疗。笔者就18F-FDG PET/CT在肿瘤PD-1/PD-L1免疫治疗中的研究进展进行综述。
-
关键词:
- 氟脱氧葡萄糖F18 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 肿瘤 /
- B7-H1抗原 /
- 免疫疗法
Abstract: Programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) signaling pathway aids the evasion of tumor immune by producing negative control signals, leading to immune tolerance and promoting progress of tumors. PD-1/PD-L1 targeted immumotherapy, the new therapeutic method of malignant tumors, can restore the immune responses of microenviroment in tumors and mediate proliferation of T lymphocytes that could kill tuomr cells. However, there are differences of immune responses in different patients. To date, there have not been valid clinicopathological biomarkers to identify responders or non-responders. 18F-FDG PET/CT is a useful, real-time and noninvasive modality for the assessment of tumor glucose metabolism. Positive expression of PD-L1 also has been shown to influent glucose metabolism in microenviroment of tumors. Thus, it is promising that 18F-FDG PET/CT could be useful to the PD-1/PD-L1 immumotherapy. This review focuses on advances of 18F-FDG PET/CT in PD-1/PD-L1 targeted immumotherapy of tumors. -
[1] 邢岩, 赵晋华. 靶向免疫检查点PD-1/PD-L1的肿瘤分子影像学研究进展[J]. 国际放射医学核医学杂志, 2019, 43(4): 356−360. DOI: 10.3760/cma.j.issn.1673-4114.2019.04.010.
Xing Y, Zhao JH. Advances of molecular imaging of immune checkpoint targeting PD-1/PD-L1 in tumors[J]. Int J Radiat Med Nucl Med, 2019, 43(4): 356−360. DOI: 10.3760/cma.j.issn.1673-4114.2019.04.010.[2] Chang CH, Qiu J, O'Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression[J]. Cell, 2015, 162(6): 1229−1241. DOI: 10.1016/j.cell.2015.08.016. [3] Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2): 123−135. DOI: 10.1056/NEJMoa1504627. [4] Nanda R, Specht J, Dees C, et al. Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)[J]. Cancer Res, 2017, 77(Suppl 4): SP6−10-03. DOI: 10.1158/1538-7445.Sabcs16-p6-10-03. [5] Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer[J]. J Clin Oncol, 2016, 34(25): 2980−2987. DOI: 10.1200/JCO.2016.66.9929. [6] Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapies targeting the PD-1 signaling pathway[J]. J Biomed Sci, 2017, 24(1): 26. DOI: 10.1186/s12929-017-0329-9. [7] Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res, 2017, 23(8): 1920−1928. DOI: 10.1158/1078-0432.CCR-16-1741. [8] Saâda-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma[J]. Ann Oncol, 2017, 28(7): 1605−1611. DOI: 10.1093/annonc/mdx178. [9] Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255−265. DOI: 10.1016/S0140-6736(16)32517-X. [10] Shukuya T, Carbone DP. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer[J]. J Thorac Oncol, 2016, 11(7): 976−988. DOI: 10.1016/j.jtho.2016.02.015. [11] Hirakata T, Fijii T, Kaira K, et al. Relationship between FDG-uptake and expression level of PD-L1 in primary ER positive/HER2 negative breast cancer[J]. Cancer Res, 2019, 79(4): 4−8. DOI: 10.1158/1538-7445.Sabcs18-pd4-08. [12] Kasahara N, Kaira K, Bao P, et al. Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma[J]. Lung Cancer, 2018, 119: 71−77. DOI: 10.1016/j.lungcan.2018.03.001. [13] 郭大鑫, 黄文霞, 黄晓丽, 等. 浸润性肺腺癌18F-FDG PET/CT SUVmax值与PD-L1蛋白表达的关系[J]. 中国胸心血管外科临床杂志, 2020, 27(3): 290−296. DOI: 10.7507/1007-4848.201908023.
Guo DX, Huang WX, Huang XL, et al. Relationship between SUVmax in 18F-FDG PET/CT and PD-L1 expression in invasivelung adenocarcinoma[J]. Chin J Clin Thoracic Cardiovasc Surg, 2020, 27(3): 290−296. DOI: 10.7507/1007-4848.201908023.[14] Kaira K, Serizawa M, Koh Y, et al. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer[J]. Lung Cancer, 2014, 83(2): 197−204. DOI: 10.1016/j.lungcan.2013.11.025. [15] Koyasu S, Kobayashi M, Goto Y, et al. Regulatory mechanisms of hypoxia-inducible factor 1 activity: two decades of knowledge[J]. Cancer Sci, 2018, 109(3): 560−571. DOI: 10.1111/cas.13483. [16] Chen C, Tang Q, Zhang Y, et al. Metabolic reprogramming by HIF-1 activation enhances survivability of human adipose-derived stem cells in ischaemic microenvironments[J]. Cell Prolif, 2017, 50(5): e12363. DOI: 10.1111/cpr.12363. [17] Zhang H, Lu CY, Fang M, et al. HIF-1α activates hypoxia-induced PFKFB4 expression in human bladder cancer cells[J]. Biochem Biophys Res Commun, 2016, 476(3): 146−152. DOI: 10.1016/j.bbrc.2016.05.026. [18] Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation[J]. J Exp Med, 2014, 211(5): 781−790. DOI: 10.1084/jem.20131916. [19] Chen RH, Chen YM, Huang G, et al. Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer[J]. Aging (Alban NY), 2019, 11(24): 12270−12277. DOI: 10.18632/aging.102567. [20] Chen RH, Zhou X, Liu JJ, et al. Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer[J]. Eur J Nucl Med Mol Imaging, 2019, 46(4): 848−854. DOI: 10.1007/s00259-018-4208-8. [21] Takada K, Toyokawa G, Okamoto T, et al. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on 18F-fluorodeoxyglucose positron emission tomography/computed tomography[J/OL]. Cancer Med, 2017, 6(11): 2552−2561[2019-12-18]. https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.1215. DOI: 10.1002/cam4.1215. [22] Dercle L, Seban RD, Lazarovici J, et al. 18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor[J]. J Nucl Med, 2018, 59(1): 15−24. DOI: 10.2967/jnumed.117.193011. [23] Weppler AM, Bhave P, De Ieso P, et al. Clinical and FDG-PET markers of immune checkpoint inhibitor (ICI) response in patients with metastatic Merkel cell carcinoma (mMCC)[J]. J Clin Oncol, 2019, 37(Suppl 15): S9540. DOI: 10.1200/JCO.2019.37.15_suppl.9540. [24] Kaira K, Higuchi T, Naruse I, et al. Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 56−66. DOI: 10.1007/s00259-017-3806-1. [25] Kong BY, Menzies AM, Saunders CAB, et al. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy[J]. Pigment Cell Melanoma Res, 2016, 29(5): 572−577. DOI: 10.1111/pcmr.12503. [26] Fredrickson J, Callahan J, Funke R, et al. Utility of FDG-PET in immunotherapy: results from a Phase II study of NSCLC patients undergoing therapy with the PD-L1 inhibitor, atezolizumab (MPDL3280A)[J]. J Nucl Med, 2016, 57(Suppl 2): S134.
计量
- 文章访问数: 2547
- HTML全文浏览量: 1719
- PDF下载量: 42